← Back to Search

Physical Therapy for Osteoarthritis (TeMPO Trial)

N/A
Waitlist Available
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Knee pain of at least 21 days duration if traumatic; no minimum duration if non-traumatic
Physician diagnosis of meniscal tear
Must not have
Daily use of strong opioids
Inflammatory arthritis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will help us to understand how physical therapy works and what protocol is best for people with knee arthritis and meniscal tears.

Who is the study for?
This trial is for adults aged 45-85 with knee pain from a meniscal tear and osteoarthritis, confirmed by MRI or X-ray. Candidates must have had knee pain for at least 21 days if it's due to injury. Exclusions include inflammatory arthritis, recent knee surgery, pregnancy, MRI contraindications, strong opioid use, recent joint therapy, nursing home residents, dementia history or worker's compensation claimants.
What is being tested?
The TeMPO Trial compares four non-surgical physical therapy regimens to see which best reduces pain and improves function in people with meniscal tears and osteoarthritis. It includes in-clinic exercises, topical therapies, home exercises and motivational texts. One group will receive placebo treatments to identify effective therapy aspects.
What are the potential side effects?
Physical therapy side effects may include temporary increased joint pain or muscle soreness following treatment sessions. Topical therapies might cause skin irritation in some individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had knee pain for at least 21 days due to an injury, or any duration if not from an injury.
Select...
My doctor diagnosed me with a torn meniscus.
Select...
I am between 45 and 85 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I use strong painkillers every day.
Select...
I have inflammatory arthritis.
Select...
I do not speak English.
Select...
I have not had joint injections in the last 4 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Pain
Secondary study objectives
30-second sit to stand
Binary treatment failure indicator
Change in function
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: 4. In-Clinic Exercise TherapyExperimental Treatment3 Interventions
Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
Group II: 3. In-Clinic Topical TherapyExperimental Treatment3 Interventions
Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
Group III: 2. Home Exercise Program + SMS MessagesExperimental Treatment2 Interventions
Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
Group IV: 1. Home Exercise ProgramExperimental Treatment1 Intervention
The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).

Find a Location

Who is running the clinical trial?

State University of New York at BuffaloOTHER
268 Previous Clinical Trials
50,762 Total Patients Enrolled
1 Trials studying Osteoarthritis
300 Patients Enrolled for Osteoarthritis
Brigham and Women's HospitalLead Sponsor
1,666 Previous Clinical Trials
11,842,587 Total Patients Enrolled
16 Trials studying Osteoarthritis
29,031 Patients Enrolled for Osteoarthritis
National Institutes of Health (NIH)NIH
2,826 Previous Clinical Trials
8,165,677 Total Patients Enrolled
20 Trials studying Osteoarthritis
3,957 Patients Enrolled for Osteoarthritis
Boston UniversityOTHER
476 Previous Clinical Trials
9,992,661 Total Patients Enrolled
12 Trials studying Osteoarthritis
5,127 Patients Enrolled for Osteoarthritis
The Cleveland ClinicOTHER
1,056 Previous Clinical Trials
1,370,738 Total Patients Enrolled
10 Trials studying Osteoarthritis
2,263 Patients Enrolled for Osteoarthritis
University of PittsburghOTHER
1,789 Previous Clinical Trials
16,358,744 Total Patients Enrolled
12 Trials studying Osteoarthritis
3,925 Patients Enrolled for Osteoarthritis
University of MelbourneOTHER
182 Previous Clinical Trials
1,281,390 Total Patients Enrolled
13 Trials studying Osteoarthritis
702,472 Patients Enrolled for Osteoarthritis
Chuck Washabaugh, PhDStudy ChairNational Institute for Arthritis, Musculoskeletal and Skin Diseases (NIAMS, NIH)

Media Library

TeMPO Home Exercise Program Clinical Trial Eligibility Overview. Trial Name: NCT03059004 — N/A
Osteoarthritis Research Study Groups: 4. In-Clinic Exercise Therapy, 3. In-Clinic Topical Therapy, 1. Home Exercise Program, 2. Home Exercise Program + SMS Messages
Osteoarthritis Clinical Trial 2023: TeMPO Home Exercise Program Highlights & Side Effects. Trial Name: NCT03059004 — N/A
TeMPO Home Exercise Program 2023 Treatment Timeline for Medical Study. Trial Name: NCT03059004 — N/A
~112 spots leftby Dec 2025